The Spectacular Conclusion of COGA I: Clinical Applications of PAX1 & JAM3 Gene Methylation Gain Attention

Along the banks of the Huangpu River, the sun blazed down, and the atmosphere inside and outside the venue was equally intense. The four-day 2024 Chinese Medical Association Obstetricians and Gynecologists Conference concluded spectacularly on August 4 in Shanghai. The conference continued its theme of "Academic Exchange, Self-Discipline and Rights Protection, and Humanistic Education," inviting several academicians and hundreds of authoritative experts in the field of obstetrics and gynecology to gather together. They hosted dozens of subject forums on standardized clinical practice, difficult and hot issues in clinical application, new concepts, and new technologies, with thousands of physician representatives registered to attend, witnessing this grand event in the field of obstetrics and gynecology.

On the afternoon of August 2, a special academic session titled "The Application Value and Achievements of PAX1/JAM3 Gene Methylation in the Diagnosis and Treatment of Cervical Cancer" was held at the Cervical Lesions Forum (Room 5). The session, chaired by Professor Shulan Zhang from Shengjing Hospital of China Medical University and presented by Professor Lihui Wei from Peking University People’s Hospital, was packed with attendees and drew widespread attention from participating physicians.

According to the latest cancer data from WHO's IARC, cervical cancer ranks as the top genital tract cancer and the second most common gynecological tumor after breast cancer. In China, there are 150,659 new cases and 55,694 deaths annually, accounting for about 22.7% and 16.0% of global figures, respectively, making it the fifth most common malignant tumor among Chinese women. The incidence and mortality rates of cervical cancer in China are increasing annually and trending towards younger patients. The current status of cervical cancer prevention and control in China still has a significant gap compared to WHO's 2023 strategic goals, posing a long and arduous task ahead.

Traditional Pap smears, cytology, and HPV testing have achieved good screening results in the past for cervical cancer prevention and control. However, they still suffer from low sensitivity or specificity, leading to missed diagnoses, transient infection panic, and over-diagnosis, among other issues. This has created opportunities for the application of innovative technologies like methylation.

Currently, DNA methylation has been included in guidelines and consensus documents such as WHO, China's Cervical Cancer Tertiary Prevention and Control Blue Book, China's Cervical Cancer Screening Guidelines, and the 2024 Consensus on DNA Methylation Biomarker Detection and Clinical Application, becoming a potential future technology for cervical cancer screening.

DNA methylation changes are early events in the progression from high-grade cervical lesions to invasive cancer and are crucial for the precise identification of CIN2+ lesions. Studies have shown a positive correlation between the high expression of specific gene methylation in cervical exfoliated cells and the occurrence of cervical cancer. Among these, PAX1 gene methylation has abundant clinical research evidence in Asian populations, while JAM3 gene methylation can compensate for missed diagnoses of adenocarcinoma and provide a basis for determining persistent infections.

JH CISPOLY’s dual-gene methylation of PAX1/JAM3 (product name: Hegongkang CISCER?) boasts excellent clinical detection performance, with a sensitivity of 89.60% and a specificity of 96.50% for detecting CIN2+. In recent years, the dual-gene methylation of PAX1/JAM3 has been extensively studied, with high-quality academic results showcased at numerous domestic and international conferences such as ESGO, EUROGIN, AOGIN, and CSCCP.

In addition to routine screening triage for high-risk HPV positive and cytology positive cases and colposcopy triage management for Type III transformation zone and adenocarcinoma patients, this satellite session emphasized the application value of JAM3/PAX1 dual-gene methylation as evidence of persistent HPV infection, cervical cancer screening, and self-sampling stratified management. It is a new technology worthy of clinical attention and application.

In the future, JAM3/PAX1 dual-gene methylation will continue to be explored in more scenarios such as precise triage, screening, monitoring, and follow-up. Through full-scenario clinical applications, the aim is to obtain high-quality multicenter clinical data, formulate clinical expert consensus on application, and establish diagnostic and treatment guidelines with Chinese characteristics.

As a high-tech enterprise focusing on the application of methylation in the field of gynecological tumors, JH CISPOLY emphasizes evidence-based application and clinical application of methylation. Currently, JAM3/PAX1 dual-gene methylation testing products have been successfully applied in hundreds of tertiary hospitals nationwide and are actively promoting their widespread use in consumer healthcare and international markets (having obtained European CE and UKCA certifications), contributing to the global strategy of eliminating cervical cancer with innovative technology. Additionally, JH CISPOLY is actively enriching its pipeline of methylation products for gynecological tumors, contributing to women's health.

About JH CISPOLY

Beijing Qrigin Poly Bio-tec Co., Ltd. is a technology enterprise driven by innovative technology and focused on health. JH CISPLY is a pioneer in the field of early diagnosis of gynecological tumors. It has developed early diagnostic products for gynecological tumors such as cervical cancer, endometrial cancer, and ovarian cancer, based on its proprietary technology and patented biomarkers, filling gaps in this field.

As women pay more and more attention to their own health, the women's health market will have great potential. In addition to the early screening and early diagnosis product line for gynecological tumors, JH CISPOLY will also establish more product pipelines related to women's health in the future, aiming to become a leading technology innovation enterprise in the women's health market.